A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001

Trial Profile

A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs APX 001 (Primary) ; APX 001 (Primary)
  • Indications Mycoses
  • Focus Adverse reactions
  • Sponsors Amplyx Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2017 Results from this and another phase I trial presented in an Amplyx Pharmaceuticals media release.
    • 09 Oct 2017 According to an Amplyx Pharmaceuticals media release, results from this trial have been presented at IDWeek 2017.
    • 21 Sep 2017 According to an Amplyx Pharmaceuticals media release, data from this study will be presented at the Infectious Diseases Society of America (IDSA) IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top